Induction of a tumor-hostile breast cancer microenvironment by metformin
二甲双胍诱导肿瘤不利的乳腺癌微环境
基本信息
- 批准号:9058123
- 负责人:
- 金额:$ 10.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-01 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AnnexinsAnti-Inflammatory AgentsAnti-inflammatoryAntidiabetic DrugsAntineoplastic AgentsAttenuatedBreastBreast Cancer CellBreast Cancer PreventionCalcium-Binding ProteinsCardiovascular systemCell DeathCell ProliferationCell SurvivalCellsCessation of lifeChemopreventive AgentChronicCoculture TechniquesCoxibsDataDevelopmentDiabetes MellitusDinoprostoneDiseaseElementsEndometrial CarcinomaEstrogensExhibitsExperimental ModelsFDA approvedFibroblastsGDF15 geneGenesGoalsHealthHyperplasiaIn VitroIncidenceInflammationInflammatoryMalignant NeoplasmsMammary NeoplasmsMediatingMeta-AnalysisMetabolicMetabolismMetforminMindModelingMyocardial InfarctionNeoplasm MetastasisPLAB ProteinParacrine CommunicationPharmaceutical PreparationsPhenotypePlayPreventiveProductionPropertyRepressionRiskRoleSignal TransductionSourceStrokeTestingTherapeuticThromboembolismTumorigenicityWomanangiogenesisautocrinecancer cellcancer chemopreventionconditioningcytokinediabetic patientin vivoinsightmRNA Expressionmalignant breast neoplasmneoplasticoverexpressionparacrinepreventtumortumor microenvironmenttumor progressiontumorigenesis
项目摘要
DESCRIPTION (provided by applicant): With regard to breast cancer chemoprevention, few drugs have been developed to disrupt the autocrine/paracrine signaling circuits which maintain the tumor-supportive microenvironment. Chronic inflammatory signaling through PGE2 (prostaglandin E2) and proinflammatory cytokines play significant roles in mediating tumor progression by promoting cancer cell proliferation. The anti-diabetic drug metformin is associated with decreased incidence of breast cancer, exhibits anti-proliferative, anti-inflammatory, effects in experimental models. However, there are few studies investigating if metformin exposure can attenuate tumor promoting autocrine/paracrine inflammatory signals which condition the breast cancer microenvironment. For this study, the goal is to ascertain the impact of metformin-modulated inflammatory signaling in the tumor microenvironment and consequently on tumor progression. PGE2, Annexin A2, and growth and Differentiation Factor 15(GDF15) are each molecules which play a distinct role in cell-extrinsic signaling in cancer and inflammation. As such, the overall hypothesis is that metformin disrupts pro-neoplastic autocrine/paracrine inflammatory signaling in breast cancer by disrupting the PGE2/annexin A2/GDF15 signaling axis. As such, the specific aims of this study include: Aim 1 will test the hypothesis that metformin-conditioning leads to cell intrinsic and cell extrinsic inhibition of BCC
proliferation and invasiveness in vitro and in vivo. Aim 2 will test the hypothesis that metformin modulates tumor-supportive inflammatory signaling in breast cancer microenvironment by repressing PGE2 and annexin A2 production, and by inducing of GDF15 expression. The long term goal of these studies will contribute to the development of metformin and similar "metabolic reconditioning drugs" as therapeutic/chemo-preventive agents by identifying the key signaling elements involved in their antineoplastic effects. More fundamentally, these studies will provide valuable insight into the intersection of metabolism and inflammation in neoplastic disease.
描述(由申请人提供):在乳腺癌化学预防方面,很少有药物能够破坏自分泌/旁分泌信号通路,而自分泌/旁分泌信号通路通过 PGE2(前列腺素 E2)和促炎细胞因子维持肿瘤支持性微环境,发挥着重要作用。抗糖尿病药物二甲双胍通过促进癌细胞增殖来介导肿瘤进展,与降低乳腺癌发病率有关,具有抗增殖、然而,很少有研究调查二甲双胍暴露是否可以减弱调节乳腺癌微环境的肿瘤促进自分泌/旁分泌炎症信号。肿瘤微环境中的炎症信号传导以及 PGE2、膜联蛋白 A2 和生长和分化因子 15 (GDF15) 都是在肿瘤进展中发挥独特作用的分子。因此,总体假设是二甲双胍通过破坏 PGE2/膜联蛋白 A2/GDF15 信号轴来破坏乳腺癌中的促肿瘤自分泌/旁分泌炎症信号。研究包括: 目标 1 将检验二甲双胍调节导致 BCC 细胞内在和细胞外在抑制的假设
目标 2 将检验二甲双胍通过抑制 PGE2 和膜联蛋白 A2 的产生以及诱导 GDF15 表达来调节乳腺癌微环境中肿瘤支持性炎症信号传导的假设。通过识别抗塑料作用中涉及的关键信号元件,为二甲双胍和类似的“代谢修复药物”作为治疗/化学预防药物的开发做出贡献。从根本上说,这些研究将为肿瘤疾病中代谢和炎症的交叉提供有价值的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher Williams其他文献
Christopher Williams的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher Williams', 18)}}的其他基金
Using Digital Health Technology to Prevent Bullying and Cyberbullying among Elementary School Students
利用数字健康技术预防小学生欺凌和网络欺凌
- 批准号:
10822435 - 财政年份:2023
- 资助金额:
$ 10.67万 - 项目类别:
An Evidence-based Approach for Bullying Prevention
预防欺凌的循证方法
- 批准号:
10192438 - 财政年份:2020
- 资助金额:
$ 10.67万 - 项目类别:
Effect of CX4945 in tamoxifen resistant BCa
CX4945 在他莫昔芬耐药 BCa 中的作用
- 批准号:
10228560 - 财政年份:2020
- 资助金额:
$ 10.67万 - 项目类别:
Effect of CX4945 in tamoxifen resistant BCa
CX4945 在他莫昔芬耐药 BCa 中的作用
- 批准号:
10458662 - 财政年份:2020
- 资助金额:
$ 10.67万 - 项目类别:
Effect of CX4945 in tamoxifen resistant BCa
CX4945 在他莫昔芬耐药 BCa 中的作用
- 批准号:
10673636 - 财政年份:2020
- 资助金额:
$ 10.67万 - 项目类别:
A High School Program for Preventing Prescription Drug Abuse
预防处方药滥用的高中计划
- 批准号:
10226253 - 财政年份:2017
- 资助金额:
$ 10.67万 - 项目类别:
A High School Program for Preventing Prescription Drug Abuse
预防处方药滥用的高中计划
- 批准号:
9980826 - 财政年份:2017
- 资助金额:
$ 10.67万 - 项目类别:
Induction of a tumor-hostile breast cancer microenvironment by metformin
二甲双胍诱导肿瘤不利的乳腺癌微环境
- 批准号:
8855851 - 财政年份:2015
- 资助金额:
$ 10.67万 - 项目类别:
Innovative Positive Juvenile Justice Tools for Youth Courts
青年法庭创新的积极少年司法工具
- 批准号:
8713202 - 财政年份:2014
- 资助金额:
$ 10.67万 - 项目类别:
Testing a Multilevel Preventive Intervention in Youth Courts
在青少年法庭测试多层次预防性干预措施
- 批准号:
9127907 - 财政年份:2014
- 资助金额:
$ 10.67万 - 项目类别:
相似国自然基金
卡萨烷选择性调控糖皮质激素受体GR功能的抗炎作用机制与新颖调控剂的设计与发现
- 批准号:82273824
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
靶向HDAC3/SIAH2蛋白复合物的HDAC3降解剂的作用机制、结构改造及非酶活功能介导的抗炎活性研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ZAP-70选择性共价抑制剂及降解剂的设计合成和抗炎活性研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于片段的P2Y14受体拮抗剂的设计、合成和抗炎活性研究
- 批准号:
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
两种民族药用植物中黄酮类ILCreg诱导剂的发现及其抗炎性肠病机制探究
- 批准号:81960777
- 批准年份:2019
- 资助金额:34 万元
- 项目类别:地区科学基金项目
相似海外基金
CLEC7A in microglia biology and Alzheimer's disease
CLEC7A 在小胶质细胞生物学和阿尔茨海默病中的作用
- 批准号:
10659940 - 财政年份:2023
- 资助金额:
$ 10.67万 - 项目类别:
Cellular and humoral immunity in Lyme arthritis
莱姆关节炎的细胞和体液免疫
- 批准号:
10317057 - 财政年份:2019
- 资助金额:
$ 10.67万 - 项目类别:
Cellular and humoral immunity in Lyme arthritis
莱姆关节炎的细胞和体液免疫
- 批准号:
10541106 - 财政年份:2019
- 资助金额:
$ 10.67万 - 项目类别: